Human iPSC-derived cells and specialized services
Axol Bioscience is committed to closing the translational gap and developing physiologically relevant in vitro systems that improve consistency and relevance in human disease modeling and compound testing.
With over a decade of hard-earned experience in the iPSC space, we are recognised as leaders in the manufacturing of high-quality, functional iPSC-derived cells and offer a range of outsourced services, including disease model creation, compound screening, assay development, reprogramming, and gene editing.
Focus areas
Do you need functional cells for your in vitro models? Functional cells & flexible production, Axol is the leading supplier of iPSC-derived cells to support research and drug discovery.
From small runs to long-lasting supply agreements, we can conduct custom production runs using cells from Axol’s iPSC library, your library, or a third-party. Matched with leading functional QC approaches to enable success in your human disease modeling.
Can we accelerate your ophthalmology program in 2025? ‘The eye is the window to the brain’ and so with cross-relevance to neuroscience and neuroinflammatory drug discovery and the rise of incidence of Dry-AMD, Axol supports a scalable high throughput, high content, physiologically relevant model for Dry-AMD.
Learn more about this blue-light activated system and how it can accelerate your research program in 2025.
Driving ALS drug discovery projects with urgency? Quality, well-characterized iPSC-derived cells are the foundation of any serious iPSC powered in vitro model. And so it is with Axol’s axoCells ALS Toolbox – motor neurons from six different donor lines including two unaffected donors, one C9orf72 carrying donor (a sibling to one of the ALS donors), and three donors each carrying significant genotypes associated with ALS, SOD1, C9orf72 and TDP43.
Axol Bioscience – reliable physiologically relevant iPSC-derived disease models
Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services. With over a decade of expertise, Axol partners with global pharmaceutical companies, contract research organizations (CROs), biotechnology firms, start-ups, and academic institutions to advance the use of iPSC-based models in drug discovery and disease research.
We operate across five key areas, neuroscience (including ALS, Alzheimer’s, Huntington’s, Parkinson’s, neuroinflammation), pain & sensation, ophthalmology (Dry-AMD, ophthal-inflammation), dermatology, and cardiovascular.
Axol offers scalable solutions including iPSC banking, reprogramming, gene editing, cell manufacturing, and quality control. The company is committed to closing the translational gap, developing physiologically relevant in vitro systems that improve consistency and relevance in human disease modeling and compound testing.
Axol is recognized for its scientific excellence, transparent collaboration, and rigorous quality standards, with manufacturing operations certified to ISO 9001:2015.
